Radhika Dhamija

Dr. Radhika Dhamija is Associate Professor of Medical Genetics and Assistant Professor of Neurology at Mayo Clinic College of Medicine and Science, serving as Consultant in Clinical Genomics, Pediatric Neurology, and Pediatric and Adolescent Medicine at Mayo Clinic in Rochester, Minnesota. Board-certified in neurology and genetics, she specializes in rare neurogenetic disorders and undiagnosed diseases.

Her education includes an MBBS from All India Institute of Medical Sciences (2005), Pediatrics residency at Western Michigan University (2009), and dual residency/fellowship training in Child Neurology and Medical Genetics at Mayo Clinic (2012-2014).

• MBBS: All India Institute of Medical Sciences (2005)
• Pediatrics Residency: Western Michigan University (2009)
• Child Neurology Residency & Chief Residency: Mayo Clinic (2012)
• Medical Genetics Fellowship: Mayo Clinic (2014)

Dr. Dhamija's research centers on neurogenetics, with emphasis on neurocutaneous syndromes (neurofibromatosis/schwannomatosis) and Autosomal Dominant Leukodystrophy. She employs whole-exome/genome sequencing to discover novel genetic diagnoses, expand clinical phenotypes of rare disorders like Hartsfield syndrome, and develop consensus care guidelines through multidisciplinary collaboration.

Her scientific contributions are recognized through awards including the Mayo Clinic Clinomics Translational Research Award (2013) and Young Investigator Award (2012).

• Mayo Clinic Clinomics Translational Research Award (2013)
• Young Investigator Award (2012)
• Multiple academic honors during medical training

As Associate Program Director for Medical Genetics Residency, she mentors future geneticists while leading clinical trials for neurofibromatosis and ADLD. Her work is supported through Mayo Clinic's Center for Individualized Medicine where she contributes to the Program for Rare and Undiagnosed Diseases and Genomic Odyssey Board.

Dr. Dhamija co-directs Mayo Clinic's Neurofibromatosis Clinic and leads the ADLD Clinical Care Center, integrating clinical expertise with research to advance therapeutics for ultra-rare disorders through the ADLD Clinical Consortium.